Afshin Dowlati

20PUBLICATIONS
163CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsPsychophysiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Apr 20, 2026
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer.

|Dec 18, 2025
Comprehensive Analysis of the Value of Dynamic Changes in Circulating Tumor DNA in Small Cell Lung Cancer.

Abhishek Ajay, Reza Ferdousi, Peronne L Joseph

|Dec 03, 2025
Roles of Restricted Mean Survival Time and Restricted Mean Time Lost in Evaluating Immune Checkpoint Inhibitor Efficacy for Extensive-Stage Small Cell Lung Cancer.

Seren Durer, Pingfu Fu, Zhengyi Chen

|Oct 24, 2025
A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies.

Dejan Juric, Daniel Anderson, Afshin Dowlati

|Jun 17, 2025
Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.

Ticiana A Leal, Yating Wang, Afshin Dowlati

|Jan 03, 2025
Assessment of targets of antibody drug conjugates in SCLC.

Abhishek Ajay, Han Wang, Ali Rezvani

Pageof 4

Frequent Collaborators

4 joint publications

Pingfu Fu

4 joint publications

Melissa Lynne Johnson

4 joint publications

Luis Paz-Ares

3 joint publications

Gary Wildey